A Trial of CMNa Combined With Preoperatie Concurrent Chemoradiotherapy for Locally Advanced ESCC

Phase 4

Terminated

• Conditions: Esophageal Neoplasms
• Interventions: Drug: Sodium Glycididazole

• Registration Number: NCT02721550
• Lead Sponsor: Shandong Cancer Hospital and Institute

Brief Summary

This is a perspective, multicenter,single arm, open label study to evaluate the efficacy and safety of treatment with CMNa combined with preoperatie concurrent chemoradiotherapy in patients with locally advanced squamous cell esophageal carcinoma . Analyses of primary objective (pathologic Complete Response) will be done as defined in the protocol.

Detailed Description

The primary end ponit of this study is pathological complete response.And the primary hypothesis is the CMNa will improve patholofical response rate and thus improve OS、DFS. Assuming bilateral a=0.05, statistical power of 80%.The total sample size is 40 cases.

Study Timeline

• Study First Submitted: 2016-03-09
• Study First Submitted QC: 2016-03-22
• Study First Posted: 2016-03-29
• Study Start: 2016-08-01
• Primary Completion: 2018-06-30
• Study Completion: 2018-06-30
• Status Verified: 2019-10
• Last Update Submitted: 2019-10-10
• Last Update Posted: 2019-10-11

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 2

Inclusion Criteria

1. Signed written informed consent prior to study entry
2. Patients with ESCC in thoracic segment which is resectable（T2-3，N0-1，M0） confirmed by imaging and pathology or cytology;
3. Patients have tumor lesions which can be objectively measured ,the length of tumor:≤8cm, the width of tumor:≤5cm;If the tumor cross the GEJ and violate the proximal stomach, the tumor must include esophagus and GEJ. The tumor is less than 2cm of the stomach
4. Not infringe bronchial wall; no esophagus-tracheal fistula.
5. normal bone marrow reserve: ANCcount ≥1500/mm3;platelet count ≥100,000/mm3,hemoglobin≥9g/dl
6. normal hepatic funcion:bilirubin level ≤1.5×ULN;AST/ALT≤1.5×ULN
7. normal renal function: serum creatinine≤1.5mg/dl and calculated creatinine clearance ≥60ml/min
8. normal cardiac function
9. ECOG PS of 0 or 1
10. Expected lifetime≥3 months
11. Subjects tumor tissue available for the relevant biomarker detection

Exclusion Criteria

1. Female subject who is during pregnancy or lactation, and the subject who have fertility don't take effective contraception during study.
2. Any mental illness or nervous system lesions or can't tell treatment response clearly (such as cerebrovascular accident sequelae)
3. Any serious uncontrolled disease and infection, such as severe heart, liver, kidney diseases or diabetes, can't complete the treatment plan
4. Patients who have other malignant lesions, except curable skin cancer (non- melanoma skin cancer),carcinoma in situ of cervix or serve disease cured for 5 years
5. Primary lesions were multifocal
6. Patients with distant metastasis. A small amount of stomach tumor violate GEJ or the distal esophageal.
7. Patients who have obvious esophageal ulcers or have above moderate pains in chest-back or have symptoms of esophageal perforation
8. received anti-cancer treatment of esophageal cancer before the group, including surgery, radiotherapy, chemotherapy (induction of chemotherapy before the group is greater than or equal to two cycles).
9. Cervical esophageal cancer confirmed by iconography
10. Not esophageal squamous carcinoma confirmed by pathology or cytology
11. History of active hepatitis

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Sodium Glycididazole	Sodium Glycididazole	Sodium Glycididazole：800mg/m2，finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy. Chemotherapy Paclitaxel:45 mg/m²,d1,week 1-4 Cisplatin:20 mg/m²,d1,week 1-4 OR Docetaxel: 75 mg / m², 1 day or divided into D1, D8 days, 21 days / cycle. Cisplatin: 75 mg / m², divided into D1-D3 days or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle. OR 5-FU: 500 mg / m² / day, divided into D1 \~ D5 for use, 21 days / cycle. Cisplatin: 75 mg / m² / day, divided into D1-D3 day or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle 3DCRT/IMRT:2.0Gy/f/day,T40Gy/20f,week 1-4

Primary Outcome Measures

Name	Time	Method
pathologic Complete Response	1 months	TRG-cited from Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G, Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Cancer, 73, 2680-2686, 1994.

Secondary Outcome Measures

Name	Time	Method
Disease-Free Survival	36 months
Overall Survival	36 months

Trial Locations

Locations (9)

Qianfoshan Hospital of Shandong; 🇨🇳 Jinan, Shandong, China

Shandong Cancer Hospital and Institute; 🇨🇳 Jinan, Shandong, China

Jining NO.1 People's Hospital; 🇨🇳 Jining, Shandong, China

Qingdao Center Medical Group; 🇨🇳 Qingdao, Shandong, China

Rizhao City People 's Hospital; 🇨🇳 Rizhao, Shandong, China

Liaocheng People Hospital; 🇨🇳 Liaocheng, Shandong, China

Fei Cheng People's Hospital; 🇨🇳 Tai'an, Shandong, China

An Qiu People's Hospital; 🇨🇳 Weifang, Shandong, China

The Fourth People's Hospitalof Zibo; 🇨🇳 Zibo, Shandong, China